Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis

Table 3 Binary logistic regression showing the prognostic value of inflammation markers

Risk factors for total NPS improvement	Univariable analysis			Multivariable analysis
Risk factors for total NPS improvement	Odds ratio	95% CI	p value	Odds ratio	95% CI	p value
Pretreatment PLR (high vs. low)	2.9	1.1–8.0	0.04	3.9	1.1–14.7	0.04
Pretreatment NLR (high vs. low)	1.7	0.7–4.7	0.27
Eosinophils (metric)	0.5	0.1–6.3	0.61
Neutrophils (metric)	0.9	0.7–1.4	0.75
Plateletets (metric)	1.0	1.0–1.0	0.73
AERD (yes vs. no)	2.4	0.9–6.7	0.08	1.8	0.5–7.3	0.40
Asthma (yes vs. no)	2.3	0.8–6.7	0.13	1.6	0.4–6.8	0.49
ESS (metric)	1.1	0.8–1.6	0.59	1.0	0.7–1.6	0.90
Age (metric)	1.0	1.0–1.1	0.51	1.0	0.9–1.0	0.24
Sex (male vs. female)	1.4	0.5–4.0	0.49	1.9	0.5–7.9	0.37
Pretreatment NPS (metric)	0.8	0.6–1.0	0.07	0.8	0.6–1.1	0.29

Total eosinophil, platelet, and neutrophil counts are presented in Giga/Liter
NPS nasal polyp score, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, CI confidence interval, AERD aspirin-exacerbated respiratory disease, ESS number of previous endoscopic sinus surgeries

ISSN: 1916-0216